Tesamorelin under 1mg: what the data says

A reader on r/peptides recently asked whether a 300 to 600 microgram dose of tesamorelin is worth taking, or whether sermorelin is the smarter choice on price and dosing convenience^[4]. The FDA label is the place to start answering it. Its lowest approved dose for tesamorelin is 1.28 mg per day, in the current Egrifta WR formulation^[1], and the trials behind the original approval used 2 mg per day. Nobody has published dosing data at 0.3 to 0.6 mg, so the real question, whether a fraction of the labeled dose does anything, does not have a published answer yet.

What the FDA label actually specifies

Tesamorelin is a synthetic analogue of GHRH, the hormone the hypothalamus uses to tell the pituitary gland to release growth hormone. It is approved in the United States, as Egrifta, for one narrow indication: reducing excess visceral abdominal fat in HIV-infected adults with lipodystrophy. The original 2010 formulation and its 2015 successor, Egrifta SV, were both dosed at 2 mg subcutaneously once daily. The current formulation, Egrifta WR, is more concentrated and carries a labeled dose of 1.28 mg once daily^[1]. Across every version the FDA has cleared, the labeled dose has stayed at or above 1 mg. There is no approved presentation, and no published trial arm, at 0.3 to 0.6 mg.

The label also lists what the drug is not for. It contraindicates use in active malignancy and in anyone with a disrupted pituitary gland, and it does not cover general body composition, sleep, or anti-aging use outside the approved HIV indication. That off-label conversation is common online and in some clinics, but it runs on a different evidence base than the approved indication, and dose has never been part of what that off-label evidence establishes.

Is a fraction of the labeled dose worth taking

The pooled analysis of the two phase 3 trials that supported approval, 806 HIV-infected patients on 2 mg tesamorelin daily for 26 weeks with a 26-week safety extension, found visceral fat dropped about 15 percent relative to placebo, and IGF-1 (the liver hormone that carries most of growth hormone's downstream effect) rose by roughly 108 ng/mL against essentially no change on placebo^[2]. That is what 2 mg does. Nobody has run the equivalent trial at 0.3 to 0.6 mg, so there is no comparable number for that range, only the general pharmacology assumption that a GHRH receptor gets less stimulation from less drug. Whether 300 to 600 mcg produces a meaningfully smaller IGF-1 response, a proportionally smaller one, or one too small to matter is not something the literature currently answers.

The literature reports doses of 1.28 to 2 mg daily, tested in a specific patient population, for a specific indication. It does not report outcomes at a third to a half of that dose, and it does not report outcomes in the general population using tesamorelin off-label for body composition at any dose. Both gaps matter for the reddit question, and neither has a shortcut.

How sermorelin actually compares

Sermorelin has its own FDA history, and it matters to the price and convenience comparison the thread is making. The FDA approved sermorelin acetate as Geref in 1997, for evaluating pediatric growth hormone deficiency and for idiopathic growth failure in children. The manufacturer, then EMD Serono, discontinued it for commercial reasons in 2008 and asked the FDA to withdraw the approval, which took effect in 2009. In 2013, following a citizen petition, the FDA formally determined that Geref was not withdrawn for reasons of safety or effectiveness^[3]. That determination keeps the door open for a generic manufacturer to file for approval, but as of this writing no FDA-approved sermorelin product is currently being marketed.

That is the detail the price comparison skips. Tesamorelin, as Egrifta, is a currently approved, FDA-labeled drug with a defined dose, a defined indication, and postmarket safety monitoring behind it. The sermorelin most people can actually buy today is compounded by a pharmacy rather than dispensed under an approved label, which puts it on a different regulatory footing even though the underlying molecule once had FDA approval of its own. Choosing between them on price alone treats two products with different regulatory status as if they were interchangeable, and they are not.

What we don't know

No published trial has tested tesamorelin below 1 mg, in any population. There is no head-to-head trial of tesamorelin against sermorelin, at any dose, and no current FDA-reviewed efficacy or manufacturing dataset for the compounded sermorelin sold today, the way there is for branded Egrifta. Readers comparing tesamorelin to other long-acting GHRH analogues sometimes also ask about CJC-1295, which has its own gap: only small early-phase human studies and no completed efficacy trial. None of these gaps are likely to close soon, since none of the drugs involved has an active phase 3 programme outside the approved tesamorelin indication.

What this means if you're weighing the options

This is educational information, not dosing or sourcing guidance. If the real choice on the table is a reduced, off-label dose of an FDA-approved drug versus a compounded alternative with a different evidence and quality-control picture, that is a decision for a prescriber who can order IGF-1 labs and weigh an individual's actual history, not one to reverse-engineer from a vendor's cartridge pricing. For the full regulatory picture on tesamorelin in the United States, see the US regulation page.